Advertisement

Unilateral 6-Hydroxydopamine Lesions of Nigrostriatal Dopaminergic Neurons Increased Cannabinoid CB1 Receptor mRNA Levels in the Rat Striatum: Possible Therapeutic Implications

  • Isabel Lastres-Becker
  • Julián Romero
  • Fernando Berrendero
  • Alberto Pérez-Rosado
  • Jorge Manzanares
  • Ana Rojo
  • Javier Fernández-Ruiz
  • Justo G. de Yebenes
  • Jose A. Ramos

Abstract

It has been recently suggested that the effects of cannabinoids on motor behavior might be different in rats with lesions of the basal ganglia than controls. In the present study, we have examined the possible alteration in the status of cannabinoid CB1 receptors in the basal ganglia of rats with unilateral lesions of nigrostriatal dopaminergic neurons caused by 6-hydroxydopamine, an animal model of Parkinson’s disease. As expected, lesioned rats exhibited a marked reduction in tyrosine hydroxylase-mRNA levels, measured by in situ hybridization, in the substantia nigra of the lesioned side. Lesioned rats also exhibited the characteristic rotational behavior after a single injection of apomorphine. Interestingly, we also found a significant increase in levels of CB1 receptor-mRNA transcripts in the lesioned side in both the lateral and medial caudate-putamen, which supports a critical role for dopamine in the control of CB1 receptor gene expression in striatal efferent neurons. This also suggests that CB1 receptor antagonists might be useful to improve movement in Parkinson’s disease.

Keywords

Tyrosine Hydroxylase Substantia Nigra Lesion Side Receptor mRNA Level Nigrostriatal Dopaminergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson, A., Anderson, J.J., Chase, T.N. and Walters, J.R., 1995, The cannabinoid agonist WIN55,212-2 and CP55,940 attenuate rotational behaviour induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway, Brain Res. 691: 106.PubMedCrossRefGoogle Scholar
  2. Consroe, P., 1998, Brain cannabinoid systems as targets for the therapy of neurological disorders, Neurobiol. Dis. 5: 534.PubMedCrossRefGoogle Scholar
  3. García-Gil, L., Ramos, J.A., Rubino, T., Parolaro, D. and Fernández-Ruiz, J.J., 1998, Perinatal (δ9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats, Neurotoxicol. Teratol. 20: 549.PubMedCrossRefGoogle Scholar
  4. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J.Jr. and Sibley, D.R., 1990, D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science 250: 1429.PubMedCrossRefGoogle Scholar
  5. Glass, M., Faull, R.L.M. and Dragunow, M., 1993, Loss of cannabinoid receptors in the susbtantia nigra in Huntington’s disease, Neuroscience 56: 523.PubMedCrossRefGoogle Scholar
  6. Herkenham, M., Lynn, A.B., de Costa, B.R. and Richfield, E.K., 1991, Neuronal localization of cannabinoid receptors in the basal ganglia of the rat brain, Brain Res. 547: 267.PubMedCrossRefGoogle Scholar
  7. Mailleux, P. and Vanderhaeghen, J.J., 1993, Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study, J. Neurochem. 61: 1705.PubMedCrossRefGoogle Scholar
  8. Maneuf, Y.P., Nash, J.E., Crossman, A.R. and Brotchie, J.M., 1996, Activation of the cannabinoid receptors by (δ9-tetrahydrocannabinol reduces GABA uptake in the globus pallidus, Eur. J. Pharmacol. 308: 161.PubMedCrossRefGoogle Scholar
  9. Maneuf, Y.P., Crossman, A.R. and Brotchie, J.M., 1997, The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1,dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson’s disease, Exp. Neurol. 148: 265.PubMedCrossRefGoogle Scholar
  10. Richfield, E.K. and Herkenham, M., 1994, Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus, Ann. Neurol. 36: 577.PubMedCrossRefGoogle Scholar
  11. Romero, J., de Miguel, R., García-Palomero, E., Fernández-Ruiz, J.J. and Ramos, J.A., 1995, Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function, Brain Res. 694: 223.PubMedCrossRefGoogle Scholar
  12. Romero, J., Berrendero, F., Pérez-Rosado, A., Manzanares, J., Rojo, A., Fernández-Ruiz, J.J., de Yébenes, J.G. and Ramos, J.A., 2000, Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen, Life Sci. 66: 485.PubMedCrossRefGoogle Scholar
  13. Sañudo-Peña, M.C., Patrick, S.L., Khen, S., Patrick, R.L. and Walker, J.M., 1998, Cannabinoid effects in basal ganglia in a rat model of Parkinson’s disease, Neurosci. Lett. 248: 171.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Isabel Lastres-Becker
    • 1
  • Julián Romero
    • 1
  • Fernando Berrendero
    • 1
  • Alberto Pérez-Rosado
    • 1
  • Jorge Manzanares
    • 1
  • Ana Rojo
    • 2
  • Javier Fernández-Ruiz
    • 1
  • Justo G. de Yebenes
    • 2
  • Jose A. Ramos
    • 1
  1. 1.Departamento de Bioquímica y Biología Molecular Facultad de MedicinaUniversidad ComplutenseMadridSpain
  2. 2.Servicio de NeurologíaFundación Jiménez DíazMadridSpain

Personalised recommendations